GC Green Cross announced on July 16 that it signed a memorandum of understanding (MOU) on July 15 with Cytiva at the Cytiva APAC Fast Trak™ Center in Songdo, Incheon. The partnership aims to establish a stable supply system for key consumables required for biopharmaceutical production and to expand collaboration on next-generation bioprocess technology.


At the global supply chain strategic cooperation signing ceremony marking the 30th anniversary of the partnership between GC Green Cross and Cytiva, Shin Woong, Head of Operations at GC Green Cross (right), and Sungpil Kim, CEO of Cytiva Korea (left), are posing for a commemorative photo. Photo by GC Green Cross

At the global supply chain strategic cooperation signing ceremony marking the 30th anniversary of the partnership between GC Green Cross and Cytiva, Shin Woong, Head of Operations at GC Green Cross (right), and Sungpil Kim, CEO of Cytiva Korea (left), are posing for a commemorative photo. Photo by GC Green Cross

View original image

This agreement was arranged to commemorate the 30th anniversary of the partnership between the two companies, and key stakeholders from both Cytiva and GC Green Cross attended the event. Building on their relationship that began with their first transaction in 1996, both parties shared strategic directions for collaboration to respond to changes in the global biopharmaceutical market environment.


Under this MOU, the two companies plan to establish a priority supply system for essential consumables in biopharmaceutical manufacturing, including virus removal filters necessary for the production of the blood product 'Alyglo'—a key item for entry into the U.S. market—in order to proactively respond to volatility in the global supply chain.


In addition, GC Green Cross intends to further enhance its global manufacturing competitiveness by expanding mRNA and cell and gene therapy (CGT) process optimization technology support and training programs utilizing the Songdo Fast Trak Center.


At the signing ceremony, Woong Shin, Chief Operating Officer of GC Green Cross, stated, "The mutual trust that has been built with Cytiva over the past 30 years has been a key foundation for GC Green Cross’s growth as a leading company in the global blood products market. This agreement marks the strategic starting point for strengthening both the stable global supply of Alyglo and our competitiveness in the development of next-generation biopharmaceuticals. It will serve as a milestone for a new 30 years of joint growth for both companies."



Cytiva is a global life sciences company under Danaher Corporation, providing technologies and services that support the entire process from biopharmaceutical development to commercial production. In particular, the Cytiva APAC Fast Trak Center in Songdo, Incheon, is one of Asia’s leading biopharma hubs, offering comprehensive support for process development, technology transfer, education, and training to help domestic and international companies achieve manufacturing capabilities that meet global standards.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing